Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
Nature Medicine
|
June 21, 2016
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
Sheng Li, Francine E Garrett-Bakelman, Stephen S Chung, et al.
Blood Neoplasia
|
January 29, 2026
The LMO2-LDB1-TAL1 complex regulates transcription networks in acute myeloid leukemia
Nicholas Dunham, Zhenjia Wang, Yaseswini Neelamraju, et al.
Blood
|
May 28, 2024
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia
Luísa Corrêa de Araújo Koury, Haesook T Kim, Maria Soledad Undurraga, et al.
Cancers
|
October 30, 2020
Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia
Isabel Weinhäuser, Diego A Pereira-Martins, Cesar Ortiz, et al.
Blood Neoplasia
|
June 2, 2025
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Jad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
Annals of Hematology
|
July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML
Lydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.
American Journal of Hematology
|
November 22, 2025
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients
Matteo Molica, Gema Miralles, Richard Dillon, et al.
Scientific Reports
|
June 27, 2020
NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia
Carolina Hassibe Thomé, Germano Aguiar Ferreira, Diego Antonio Pereira-Martins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
Curtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.
Blood
|
November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
Nature Medicine
|
June 21, 2016
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
Sheng Li, Francine E Garrett-Bakelman, Stephen S Chung, et al.
Blood Neoplasia
|
January 29, 2026
The LMO2-LDB1-TAL1 complex regulates transcription networks in acute myeloid leukemia
Nicholas Dunham, Zhenjia Wang, Yaseswini Neelamraju, et al.
Blood
|
May 28, 2024
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia
Luísa Corrêa de Araújo Koury, Haesook T Kim, Maria Soledad Undurraga, et al.
Cancers
|
October 30, 2020
Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia
Isabel Weinhäuser, Diego A Pereira-Martins, Cesar Ortiz, et al.
Blood Neoplasia
|
June 2, 2025
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS
Jad Othman, Ho Pui Jeff Lam, Sarah Leong, et al.
Annals of Hematology
|
July 8, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML
Lydia Kretschmer, Leo Ruhnke, Christoph Schliemann, et al.
American Journal of Hematology
|
November 22, 2025
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients
Matteo Molica, Gema Miralles, Richard Dillon, et al.
Scientific Reports
|
June 27, 2020
NTAL is associated with treatment outcome, cell proliferation and differentiation in acute promyelocytic leukemia
Carolina Hassibe Thomé, Germano Aguiar Ferreira, Diego Antonio Pereira-Martins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
Curtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.
Blood
|
November 1, 2021
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser, Sylvie D Freeman, Gert J Ossenkoppele, et al.
Page
of 11